Clinical Trial Update: Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours [Phase 1]

View source ↗

Summary

Phase 1 study assessing the safety and tolerability of intravenous PG545 (pixatimod) in patients with advanced solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• PG545 (pixatimod)

Snippet

Sponsor: Zucero Pty Ltd | Conditions: Advanced Solid Tumours | Phase 1 | Status: COMPLETED